Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with hypogonadotropic hypogonadism, either congenital or acquired~* Have low circulating levels of testosterone~* Have low circulating levels of gonadotropins (follicle stimulating hormone \[FSH\]; luteinizing hormone)~* Presence of both scrotal testes~* Have azoospermia (no measurable level of sperm)~* Adequate replacement of other pituitary hormones~* Good general physical and mental health~Exclusion Criteria:~* Primary hypogonadism, such as Klinefelter's syndrome~* History of unilateral or bilateral cryptorchidism (maldescended testes)~* History or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage III, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy~* Treated with FSH, hCG or gonadotropin-releasing hormone (GnRH) within previous 3 months or for more than 1 month within previous 6 months~* Proven spermatogenesis with hCG treatment alone~* Previous unsuccessful attempt with hCG in combination with human menopausal gonadotropin (hMG)/FSH to achieve spermatogenesis~* Required a dose of hCG of more than 6000 international units (IU) per week in a previous attempt to normalize T levels~* Untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study~* History or presence (known or suspected) of testicular, prostatic or breast cancer~* Prostate pathology of clinical importance~* Past or present oncologic treatment (chemo/radiotherapy)~* Diabetes mellitus~* Clinically significant, untreated hyperprolactinaemia~* Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)~* Tested positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C~* User of recreational or illicit drugs or has had a recent history (within the past year) of drug abuse or dependence, or increased alcohol consumption~* Allergy/sensitivity to gonadotropins or its/their excipients~* Has received within previous 1 month or plans to use: Hormonal preparations other than the study medication, drugs that are known to impair testicular function, agents known to affect sex hormone secretion and/or drugs that are known or suspected to be teratogenic~* Used any investigational drugs within three months or actively participating in another study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Corifollitropin alfa 150 μg + hCG (Type: EXPERIMENTAL): During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).